Abstract:BACKGROUND, AIM, AND METHODS: Alpha interferon is the generally approved therapy for HBe antigen positive patients with chronic hepatitis B, but its efficacy is limited. Lamivudine is a new oral nucleoside analogue which potently inhibits hepatitis B virus (HBV) DNA replication. To investigate the possibility of an additive effect of interferon-lamivudine combination therapy compared with interferon or lamivudine monotherapy, we conducted a randomised controlled trial in 230 predominantly Caucasian patients with hepatitis B e antigen (HBeAg) and HBV DNA positive chronic hepatitis B. Previously untreated patients were randomised to receive: combination therapy of lamivudine 100 mg daily with alpha interferon 10 million units three times weekly for 16 weeks after pretreatment with lamivudine for eight weeks (n=75); alpha interferon 10 million units three times weekly for 16 weeks (n=69); or lamivudine 100 mg daily for 52 weeks (n=82). The primary efficacy end point was the HBeAg seroconversion rate at week 52 (loss of HBeAg, development of antibodies to HBeAg and undetectable HBV DNA). Results: The HBeAg seroconversion rate at week 52 was 29% for the combination therapy, 19% for interferon monotherapy, and 18% for lamivudine monotherapy (p=0.12 and p=0.10, respectively, for comparison of the combination therapy with interferon or lamivudine monotherapy). The HBeAg seroconversion rates at week 52 for the combination therapy and lamivudine monotherapy were significantly different in the per protocol analysis (36% (20/56) v 19% (13/70), respectively; p=0.02). The effect of combining lamivudine and interferon appeared to be most useful in patients with moderately elevated alanine aminotransferase levels at baseline. Adverse events with the combination therapy were similar to interferon monotherapy; patients receiving lamivudine monotherapy had significantly fewer adverse events. Conclusions: HBeAg seroconversion rates at one year were similar for lamivudine monotherapy (52 weeks) and standard alpha interferon therapy (16 weeks). The combination of lamivudine and interferon appeared to increase the HBeAg seroconversion rate, particularly in patients with moderately elevated baseline aminotransferase levels. The potential benefit of combining lamivudine and interferon should be investigated further in studies with different regimens of combination therapy.

Interferon and lamivudine combination therapy versus lamivudine monotherapy for hepatitis B e antigen-negative hepatitis B treatment: a meta-analysis of randomized controlled trials.

Interferon and Lamivudine Combination Therapy Versus Lamivudine Monotherapy for Hepatitis B E Antigen-Negative Hepatitis B Treatment:A Meta-Analysis of Randomized Controlled Trials

Interferon-α Combined with Lamivudine Versus Lamivudine Monotherapy for the Emergence of YMDD Mutations in Chronic Hepatitis B Infection: a Meta-Analysis of Randomized Controlled Trials.

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance.

Peginterferon Alfa-2A Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-negative Chronic Hepatitis B.

Interferon-α Combined with Lamivudine in the Treatment of Chronic Hepatitis

Randomized, Three-Arm Study To Optimize Lamivudine Efficacy In Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients

Comparison of lamivudine or interferon monotherapy and sequential therapy in chronic hepatitis B: a random controlled trial]

Comparison of lamivudine and alpha-interferon combination with alpha-interferon alone in the treatment of HBeAg-positive chronic hepatitis B

Efficacy of Combined Therapy in Patients with Hepatitis B Virus-Related Decompensated Cirrhosis.

Treatment With Lamivudine Versus Lamivudine And Thymosin Alpha-I For E Antigen-Positive Chronic Hepatitis B Patients: A Meta-Analysis

Comparative meta-analysis of adefovir dipivoxil monotherapy and combination therapy of adefovir dipivoxil and lamivudine for lamivudine-resistant chronic hepatitis B.

Lamivudine for HBeAg Positive Chronic Hepatitis B: A Meta-analysis of Randomized Controlled Trials

Interferon‐alpha Plus Adefovir Combination Therapy Versus Interferon‐alpha Monotherapy for Chronic Hepatitis B Treatment: A Meta‐analysis

Clinical Study of IFNα-2b Alone or in Combination with Lamivudine for HBeAg Positive Chronic Hepatitis B

Therapeutic Efficacy of Combination Therapy with Interferon and a Nucleoside Analogue for Treating Chronic Hepatitis B Patients

Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis.

Clinical Evaluation of Iamivudine Alone or Combined with Inteferon Alpha As Antiviral Therapy for Patients with Chronic Hepati-Tis B

Comparison of the efficacy of lamivudine combined adefovir dipivoxil and entecavir monotherapy in the treatment of naive patients with chronic hepatitis B：a Meta analysis

A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B.